A carregar...
EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies
An increasing number of innovative oncology monoclonal antibodies (mAbs) have been introduced into the global market, and biosimilar versions have now also been approved in Europe. Being complex to develop and difficult to manufacture, the biosimilar is a drug similar but not identical in physicoche...
Na minha lista:
| Publicado no: | Int J Clin Pharm |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer International Publishing
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6132979/ https://ncbi.nlm.nih.gov/pubmed/30094558 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11096-018-0709-6 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|